Breast Cancer (Therapy)

U.S. Experts Recommend Limiting Cancer Drug Use To Five Years

Published in Women's Health Weekly, December 11th, 1995

The U.S. National Cancer Institute (NCI) is recommending that doctors limit use of the drug tamoxifen in the treatment of breast cancer to five years. A study showed there was no benefit from longer use.

The federal agency issued a clinical alert November 30, 1995 to 22,000 cancer doctors.

Tamoxifen, sold under the name Nolvadex, is prescribed as additional therapy after breast cancer surgery for women diagnosed with early stage disease.

An NCI-sponsored study comparing the effect of using tamoxifen for five years and for 10 years after surgery found that the longer-term use of the drug was unlikely to provide any additional...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (1995-12-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry